Probably a very specialist operation, requiring high capex and operating costs.
Unless you can justify volumes, subcontract will be tha best option.
Can anyone corroporate? |
Not the best situation relying on a 3rd party, why not use some capital to get the situation resolved in house. |
Doesn't mean to say that the customers will not migrate to another suppiler.
Were I a customer I would review my long therm strategy and options.
Too many negatives do not make a positive. |
Storm in a teacup really. What really is an "oh look, I have just broken a finger nail" moment is being treated by some as a major debilitation. I suspect that those with the jitters are already out. |
Temporary non fault plus revenue will come in, just at a different point. |
S/P down today, although failure of equipment out of their control. |
Uh oh... Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced woundcare specialist company, has today been notified by one of its third party medical device sterilisation partners of a failure at one of their UK e-beam sterilisation facilities. Consequently, many of the December orders for the Company's topical adhesive product, Liquiband®, will not be sterilised and shipped to customers during this financial year ending 31 December 2019. The full financial impact will not be known until after the closing of the financial year but it is potentially up to £2 million of EBITDA. |
S/P recovered to 260p+ on no news which is positive. I have said before IMHO AMS need to re-establish a partnership deal in the USA before we can recover to previous highs. Trading statement made last year Dec 18th may have good news. |
Plenty of six-figure trades gone through today. |
Something’s gotta be bubbling under.... |
I would be happy if someone were interested in them. Some positive news would be nice on developments in the USA. |
Offer for CSRT, European rather than US. Is AMS on any radars. |
Buy of 2.1m shares shown late. |
To diversify in the medical field, I bought BXP not so long ago, quite pleased to see the share price on the rise, more to come I would think as the PE-Ratio is extraordinary low for this fast growing company. For those with some spare cash, have a look, don't take my word for it, DYOR. |
AMS must win the award for having the mmost apathetic investors.
Zzzz.... |
I do feel that the share price will be at the lower end of £2+ until their are some positive news on products or a new partner in the USA. The share price at these levels may attract an approach from a predator, in saying that how much is AMS valued at all IMHO. |
I can understand a 10% drop on the disappointing update, which would put us at c.270p.
It's then up to the company to convince 'the market' just exactly what their 'Board expectations' are in performance terms.
That should then underpin the share price |
Better week for the share price, I wonder if the analysts have assessed AMS and maybe spoken to them and are confident that AMS will get US market back on track. |
Petty cash. |
Good to see this buy maybe the 1st step of the climb back North ---
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced woundcare specialist company, announces that Chris Meredith, Chief Executive Officer, purchased ordinary shares of 5 pence each in the capital of the Company ("Ordinary Shares") on 13 September 2019, at a price of 224p.
Chris Meredith -
Chief Executive Officer
13 September 2019
buy 8,800
holding 1,503,377
increase 0.7% |
Looks like bigger buyers started investing back, the price is bouncing back now, so even if this recover to 250, that's 11% profit for investors |
IMHO I feel that AMS will be seriously looked at as a potential takeover target at this share price level. If we are not bought by a predator it will take a considerable length of time to recover £3+. |
I think their first job is to reassure their major holders that they've not taken their eye off the ball.
While a drop-off in Liquiband sales was flagged up in June, the consequences for the share price seem to have come as a surprise. |
P/E and PEG ratios are all well and good but AMS need to get their act together in the USA bite the bullet and engage with a partner and as a matter of urgency. |
According to ADVFN Financials, at 226p, AMS still has a PEG Factor of 1.82.
No wonder the share price took a bashing at >£3! |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
